East West Petroleum Provides Update on Special Distribution, Name Change and Consolidation
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2025) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") wishes to provide an update on the capital reduction and spe...
East West Petroleum Shareholders Approve Capital Reduction and All Other Matters at the Annual and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to announce that at the Annual and Special Meeting...
JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition
IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition by Edwards Life...
Edwards Lifesciences Corporation (EW) Q2 2025 Earnings Call Transcript
Edwards Lifesciences Corporation (NYSE:EW ) Q2 2025 Earnings Conference Call July 24, 2025 5:00 PM ET Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian -...
Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings
EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over year.
Curious about Edwards Lifesciences (EW) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...
Should You Add Edwards Lifesciences Stock to Your Portfolio Now?
EW gains traction with surgical tech and TAVR growth, but macro pressures and FX headwinds weigh on margins.
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025...
Trade Tracker: Bill Baruch buys Edwards Lifesciences
Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest buy.
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
Edwards Lifesciences raises 2025 sales forecast after robust quarter
Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment.
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its ...
Edwards Lifesciences Corporation (EW) Q4 2024 Earnings Call Transcript
Edwards Lifesciences Corporation (NYSE:EW ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zo...
Related Companies